Event Type
Disclosure
Voluntary
Variant
8-K
of this Current Report on Form 8-K, including the information in t he press release and the Investor Presentation at tached as Exhibits 99.1 and 99.2 to this Cu
Other Events. On February 2, 2026, the Company reported the following interim results from the combination cohort of its Phase 2a extension study: • 19 particip
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Skye Bioscience, Inc. dated February 2, 2026 99.2 Investor Present